Comparison · NCT00716079-0476ddc8
Intensive Blood-Pressure Lowering vs Guideline-Recommended Blood-Pressure Lowering: A Composite of Death or Dependency, With Dependency Being Defined by a Score of 3 to 5 on the Modified Rankin Scale (mRS)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Intensive Blood-Pressure Lowering vs Guideline-Recommended Blood-Pressure Lowering: A Composite of Death or Dependency, With Dependency Being Defined by a Score of 3 to 5 on the Modified Rankin Scale (mRS). Trial comparisons, record NCT00716079-0476ddc8. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00716079-0476ddc8
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.52 | 0.494 | 0.547 | wilson | |
| Risk in group 2 | 0.556 | 0.53 | 0.582 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0357 | -0.0725 | 0.00128 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.936 | 0.874 | 1 | log | |
| Odds ratio, group 1 over group 2 | 0.866 | 0.746 | 1.01 | log | |
| Number needed to treat, for one fewer participant with the outcome on Intensive Blood-Pressure Lowering than on Guideline-Recommended Blood-Pressure Lowering | 28 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Intensive Blood-Pressure Lowering | Intensive Blood pressure (BP) lowering therapy is given via an intravenous drip for 24 hours. The target is to reach a systolic BP \<140mmHg within 1 hour.~Blood pressure management policies : The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets. | 719 | 1,382 | OG000 |
| Group 2 | Guideline-Recommended Blood-Pressure Lowering | Patients will receive management of BP that is based on a standard guideline, as published by the American Heart Association (AHA). The attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, intravenous treatment may be started until the target systolic BP of 180 mmHg is achieved.~Blood pressure management policies : The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets. | 785 | 1,412 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- A Composite of Death or Dependency, With Dependency Being Defined by a Score of 3 to 5 on the Modified Rankin Scale (mRS)
- Description
- Time frame
- 90 days
- Population
- In the intensive group 12 patients were alive at 90 days but missing data on mRS (required for primary outcome), and 9 patients in the guideline group
Source ClinicalTrials.gov
Trial
- Title
- The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial
- NCT number
- NCT00716079
- Phases
- NA
- Conditions
- Intracerebral Hemorrhage, Stroke, Hypertension
- Interventions
- Blood pressure management policies
- Lead sponsor
- The George Institute
- Results first posted
- 2013-10-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00716079?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00716079-0476ddc8